首页> 外文期刊>Chemical research in toxicology >Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones.
【24h】

Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones.

机译:他莫昔芬类似物的潜在毒性代谢产物的合成和反应性:屈洛昔芬和托瑞米芬邻醌。

获取原文
获取原文并翻译 | 示例
       

摘要

Tamoxifen remains the endocrine therapy of choice in the treatment of all stages of hormone-dependent breast cancer. However, tamoxifen has been shown to increase the risk of endometrial cancer which has stimulated research for new effective antiestrogens, such as droloxifene and toremifene. In this study, the potential for these compounds to cause cytotoxic effects was investigated. One potential cytotoxic mechanism could involve metabolism of droloxifene and toremifene to catechols, followed by oxidation to reactive o-quinones. Another cytotoxic pathway could involve the oxidation of 4-hydroxytoremifene to an electrophilic quinone methide. Comparison of the amounts of GSH conjugates formed from 4-hydroxytamoxifen, droloxifene, and 4-hydroxytoremifene suggested that 4-hydroxytoremifene is more effective at formation of a quinone methide. However, all three substrates formed similar amounts of o-quinones. Both the tamoxifen-o-quinone and toremifene-o-quinone reacted with deoxynucleosides to give corresponding adducts. However, the toremifene-o-quinone was shown to be considerably more reactive than the tamoxifen-o-quinone in terms of both kinetic data as well as the yield and type of deoxynucleoside adducts formed. Since thymidine formed the most abundant adducts with the toremifene-o-quinone, sufficient material was obtained for characterization by (1)H NMR, COSY-NMR, DEPT-NMR, and tandem mass spectrometry. Cytotoxicity studies with tamoxifen, droloxifene, 4-hydroxytamoxifen, 4-hydroxytoremifene, and their catechol metabolites were carried out in the human breast cancer cell lines S30 and MDA-MB-231. All of the metabolites tested showed cytotoxic effects that were similar to the parent antiestrogens which suggests that o-quinone formation from tamoxifen, droloxifene, and 4-hydroxytoremifene is unlikely to contribute to their cytotoxicity. However, the fact that the o-quinones formed adducts with deoxynucleosides in vitro implies that the o-quinone pathway might contribute to the genotoxicity of the antiestrogens in vivo.
机译:他莫昔芬仍然是治疗激素依赖型乳腺癌所有阶段的首选内分泌治疗药物。然而,已显示他莫昔芬会增加子宫内膜癌的风险,从而刺激了对新的有效抗雌激素如屈洛昔芬和托瑞米芬的研究。在这项研究中,研究了这些化合物引起细胞毒性作用的潜力。一种潜在的细胞毒性机制可能涉及屈洛昔芬和托瑞米芬代谢为儿茶酚,然后氧化为反应性邻醌。另一种细胞毒性途径可能涉及4-羟基托勒米芬氧化成亲电子醌甲基化物。比较由4-羟基他莫昔芬,屈洛昔芬和4-羟基托瑞米芬形成的GSH缀合物的量,表明4-羟基托瑞芬在形成醌甲基化物方面更有效。然而,所有三种底物形成相似量的邻醌。他莫昔芬-邻醌和托瑞米芬-邻醌都与脱氧核苷反应生成相应的加合物。然而,就动力学数据以及所形成的脱氧核苷加合物的产率和类型而言,托瑞米芬-邻醌显示出比他莫昔芬-邻醌显着更高的反应性。由于胸苷与托瑞米芬-邻醌形成最丰富的加合物,因此获得了足够的材料用于表征(1)H NMR,COSY-NMR,DEPT-NMR和串联质谱。在人乳腺癌细胞系S30和MDA-MB-231中进行了他莫昔芬,屈洛昔芬,4-羟基他莫昔芬,4-羟基托米芬及其儿茶酚代谢产物的细胞毒性研究。所有测试的代谢物均显示出与母体抗雌激素相似的细胞毒性作用,这表明他莫昔芬,屈洛昔芬和4-羟基托瑞米芬形成邻苯二酚不太可能对其细胞毒性做出贡献。然而,邻醌在体外与脱氧核苷形成加合物的事实表明,邻醌途径可能在体内促进了抗雌激素的基因毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号